TAS::75 0849::TAS

Oranoxis, Inc., San Diego CA

Investigators

Abstract

Different patients react very differently to chemotherapeutic cancer drugs, and are variably susceptible to drug side effects. Many patients are therefore currently not receiving adequate levels of those drugs. A personalized monitoring of toxic drug metabolites would greatly aid physicians to accurately personalize drug dosage. We propose to develop a rapid oral fluid test of a panel of small drug metabolites for personalized diagnostic monitoring during treatment. We will utilize our patented design for a "discontinuous chromatographic capillary flow solid phase assay", The test can be designed both for home self-monitoring by the patient (over-the-counter device) and for use by physicians in clinics (point-of-care). The key features include: (i), highly sensitive detection of small molecule drug metabolites;(ii), an integrated oral fluid collection design that minimizes sample variability in viscosity, pH and contents, and provides sufficient sample backupvolumes for subsequent confirmatory tests;(iii), a user-friendly, low cost and disposable device.